# Guselkumab

## Tremfya inj 100mg/1mL

| TAH Drug Code      | [ITREM](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ITREM)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | 1. **Plaque Psoriasis** Indicated for the treatment of adults with moderate to severe plaque psoriasis who are appropriate candidates for systemic therapy or phototherapy. 2. **Palmoplantar Pustulosis** Indicated for the treatment of adults with moderate to severe palmoplantar pustulosis who have not responded effectively to traditional therapies. 3. **Psoriatic Arthritis** Indicated for the treatment of adults with active psoriatic arthritis. 4. **Pustular Psoriasis** Indicated for the treatment of adults with moderate to severe pustular psoriasis who have not responded effectively to traditional therapies. |
| Dosing             | SC， plaque psoriasis， palmoplantar pustulosis， psoriasis arthritis 100 mg at week 0 and week 4， followed by 100 mg every 8 weeks.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Contraindications  | History of serious hypersensitivity reaction to guselkumab or to any of the excipients.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Adverse Effects    | Common Respiratory: Bronchitis (1.6% )， Upper respiratory infection (14.3% ) Serious Immunologic: Anaphylaxis， Hypersensitivity reaction Respiratory: Tuberculosis Other: Infectious disease (23% )                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| More Info          | [UpToDate](https://www.uptodate.com/contents/guselkumab-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

